This March, Ponesimod (PONVORY) received approval by the FDA for the treatment of patients with relapsing forms of multiple sclerosis (MS).

It is one of four sphingosine-1-phosphate (S1P) receptor modulators (others are -fingolimod, siponimod, and ozanimod) that bind selectively to S1P1 receptors, identified in having a pivotal role in the regulation of lymphocyte trafficking in multiple sclerosis.

Ponesimod contains 1,3-thiazolidine moiety in its backbone.

We have made a set of Building Blocks, which contain 1,3-thiazolidine parts – the perfect start for your research!